Related Experiment Video

Updated: Dec 18, 2025

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.3K

Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure

Dino Mirić1, Darija Baković1,2, Davor Eterović2,3

  • 1Department of Cardiology, University Hospital Split, Split, Croatia.

Journal of Cardiovascular Translational Research
|June 20, 2020
PubMed

Insights

Sacubitril-valsartan significantly improved heart function, specifically left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS), in patients with acute decompensated heart failure (ADHF) over three months.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Echocardiography

Background:

  • Limited data exists on sacubitril-valsartan's echocardiographic effects in acute decompensated heart failure (ADHF).
  • Standard angiotensin inhibition therapies are common for ADHF.

Purpose of the Study:

  • To evaluate the impact of sacubitril-valsartan on echocardiographic parameters in ADHF patients.
  • To compare sacubitril-valsartan with traditional angiotensin inhibition therapy.

Main Methods:

  • Prospective enrollment of 68 ADHF patients into sacubitril-valsartan (S/V) or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) groups.
  • Two-dimensional speckle tracking echocardiography (2D-STE) used at baseline and 3 months.
  • Comparison of changes in LVEF and global longitudinal strain (GLS) between groups.

Main Results:

  • Sacubitril-valsartan group showed significant improvements in LVEF (27% to 34.5%) and GLS (-6.6% to -9.4%) after 3 months.
  • No significant improvements were observed in the ACEi/ARB group.
  • Greater improvement in LVEF and GLS was noted in non-ischemic cardiomyopathy patients.

Conclusions:

  • Three-month treatment with sacubitril-valsartan improves LVEF and GLS in ADHF patients compared to standard therapy.
  • Sacubitril-valsartan demonstrates a positive effect on cardiac function in ADHF.
  • Further research into sacubitril-valsartan's role in ADHF is warranted.

Keywords:
Acute decompensated heart failureGlobal longitudinal strainHeart failureSacubitril/valsartanTwo-dimensional speckle tracking echocardiography

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

3.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
790
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
143
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
573
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
358
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
259
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
261